Products Categories
CAS No.: | 22232-71-9 |
---|---|
Name: | Mazindol |
Article Data: | 29 |
Molecular Structure: | |
Formula: | C16H13ClN2O |
Molecular Weight: | 284.745 |
Synonyms: | 3H-Imidazo[2,1-a]isoindol-5-ol,5-(p-chlorophenyl)-2,5-dihydro- (8CI);5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole;5-(p-Chlorophenyl)-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ol;5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol;5-(p-Chlorophenyl)-5-hydroxy-2,3-dihydro-5H-imidazo[2,1-a]isoindole;5-Hydroxy-5-p-chlorophenyl-2,3-dihydro-5H-imidazo[2,1-a]isoindole;AN 448;Magrilon;Mazanor;Mazildene;Mazindol;SaH 42548;Sanorex;Terenac;Teronac; |
EINECS: | 244-857-0 |
Density: | 1.399 g/cm3 |
Melting Point: | 215-217°C |
Boiling Point: | 454.908 °C at 760 mmHg |
Flash Point: | 228.921 °C |
Solubility: | DMSO: 10 mg/mL |
Appearance: | White solid |
Hazard Symbols: | T |
Risk Codes: | 23/24/25 |
Safety: | 36/37/39-45 |
Transport Information: | UN 2811 6.1/PG 2 |
PSA: | 35.83000 |
LogP: | 1.98270 |
The CAS register number of Mazindol is 22232-71-9. It also can be called as 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- and the systematic name about this chemical is 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol. The molecular formula about this chemical is C16H13ClN2O and the molecular weight is 284.74. Classification code about this chemical are Adrenergic Agents, Adrenergic uptake inhibitors, Anorexic, Central Nervous System Agents, Central nervous system stimulants, Dopamine Agents Dopamine uptake inhibitors Drug / Therapeutic Agent Human, Data, Mutation data, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors and Reproductive Effect.
Physical properties about Mazindol are: (1)ACD/LogP: 1.28; (2)ACD/LogD (pH 5.5): -0.72; (3)ACD/LogD (pH 7.4): -0.72; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1.19; (7)ACD/KOC (pH 7.4): 1.19; (8)#H bond acceptors: 3; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 2; (11)Polar Surface Area: 24.83Å2; (12)Index of Refraction: 1.704; (13)Molar Refractivity: 79.08 cm3; (14)Molar Volume: 203.5 cm3; (15)Polarizability: 31.35x10-24cm3; (16)Surface Tension: 55.6 dyne/cm; (17)Enthalpy of Vaporization: 75.3 kJ/mol; (18)Boiling Point: 454.9 °C at 760 mmHg; (19)Vapour Pressure: 4.57E-09 mmHg at 25°C.
The Mazindol is a central nervous system stimulant. It is a tricyclic compound. It is used in short-term (i.e., a few weeks) treatment of exogenous obesity, in combination with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2), or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.and it is used as appetite inhibitors for lose weight.It is a sympathomimetic amine, which is similar to amphetamine. It stimulates the central nervous system, which increases heart rate and blood pressure, and decreases appetite. Sympathomimetic anoretics (appetite suppressants) are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks of treatment. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Like other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to act as a reuptake inhibitor of norepinephrine.
This chemical can be produced by following reaction:
When you are using this chemical, please be cautious about it as the following:
This chemical is toxic by inhalation, in contact with skin and if swallowed. When you are using it, wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
You can still convert the following datas into molecular structure:
(1)SMILES: Clc1ccc(cc1)C4(O)c2c(cccc2)/C3=N/CCN34
(2)InChI: InChI=1/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
(3)InChIKey: ZPXSCAKFGYXMGA-UHFFFAOYAE
(4)Std. InChI: InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
(5)Std. InChIKey: ZPXSCAKFGYXMGA-UHFFFAOYSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LDLo | oral | 9mg/kg (9mg/kg) | Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 27, Pg. 598, 1968. | |
mouse | LD50 | intraperitoneal | 90mg/kg (90mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 214, Pg. 285, 1975. | |
mouse | LD50 | oral | 44800ug/kg (44.8mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
mouse | LD50 | subcutaneous | 235mg/kg (235mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
rabbit | LD50 | oral | 98mg/kg (98mg/kg) | Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 27, Pg. 598, 1968. | |
rat | LD50 | intraperitoneal | 91200ug/kg (91.2mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
rat | LD50 | oral | 36300ug/kg (36.3mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
rat | LD50 | subcutaneous | 1107mg/kg (1107mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
women | TDLo | oral | 140ug/kg/1W-I (0.14mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | American Journal of Psychiatry. Vol. 141, Pg. 1497, 1984. |